{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:39:36Z","timestamp":1780637976499,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics"},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01499-z","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T12:36:18Z","timestamp":1735907778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome \/ toxic epidermal necrolysis"],"prefix":"10.1007","author":[{"given":"Zhaoquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"1","key":"1499_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1358\/dot.2015.51.1.2250387","volume":"51","author":"J McDermott","year":"2015","unstructured":"McDermott J, Jimeno A, Pembrolizumab (2015) PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc) 51(1):7\u201320. https:\/\/doi.org\/10.1358\/dot.2015.51.1.2250387","journal-title":"Drugs Today (Barc)"},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","volume":"135","author":"K Nosaki","year":"2019","unstructured":"Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M et al (2019) Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 135:188\u2013195. https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.004","journal-title":"Lung Cancer"},{"issue":"4","key":"1499_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA et al (2021) Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 22(4):512\u2013524. https:\/\/doi.org\/10.1016\/S1470-2045(21)00005-X","journal-title":"Lancet Oncol"},{"issue":"9","key":"1499_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(9):1133\u20131144. https:\/\/doi.org\/10.1016\/S1470-2045(22)00487-9","journal-title":"Lancet Oncol"},{"issue":"3","key":"1499_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/10781552221074374","volume":"29","author":"OK Mashni","year":"2023","unstructured":"Mashni OK, Baba DW, Mahmoud AN, Qur\u2019an TO (2023) Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab. J Oncol Pharm Pract 29(3):577\u2013581. https:\/\/doi.org\/10.1177\/10781552221074374","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"1499_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects Associated with Immune Checkpoint inhibitors: a systematic review and Meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"5","key":"1499_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3390\/cancers14051237","volume":"14","author":"L Villa-Crespo","year":"2022","unstructured":"Villa-Crespo L, Podlipnik S, Anglada N, Izquierdo C, Giavedoni P, Iglesias P et al (2022) Timeline of adverse events during Immune Checkpoint inhibitors for Advanced Melanoma and their impacts on Survival. Cancers (Basel) 14(5):1237. https:\/\/doi.org\/10.3390\/cancers14051237","journal-title":"Cancers (Basel)"},{"key":"1499_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/PPA.S285256","volume":"15","author":"DA Perwitasari","year":"2021","unstructured":"Perwitasari DA, Febriana SA, Tristiana RS (2021) Quality of Life of Drug Reaction with Eosinophilia and systemic symptom (DRESS) and Stevens-Johnson syndrome (SJS) and\/or toxic epidermal necrolysis (TEN) patients. Patient Prefer Adherence 15:329\u2013335. https:\/\/doi.org\/10.2147\/PPA.S285256","journal-title":"Patient Prefer Adherence"},{"key":"1499_CR9","doi-asserted-by":"publisher","unstructured":"Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O (2017) Severe cutaneous adverse reactions to drugs. Lancet;390(10106):1996\u20132011. doi: 10.1016\/S0140-6736(16)30378-6. Epub 2017 May 2. Erratum in: Lancet. 2017;390(10106):1948. https:\/\/doi.org\/10.1016\/S0140-6736(17)31656-2","DOI":"10.1016\/S0140-6736(17)31656-2"},{"issue":"1","key":"1499_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","volume":"6","author":"KD White","year":"2018","unstructured":"White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B et al (2018) SJS\/TEN 2017: building multidisciplinary networks to Drive Science and translation. J Allergy Clin Immunol Pract 6(1):38\u201369. https:\/\/doi.org\/10.1016\/j.jaip.2017.11.023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"1499_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/medicina57090895","volume":"57","author":"R Frantz","year":"2021","unstructured":"Frantz R, Huang S, Are A, Motaparthi K (2021) Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Med (Kaunas) 57(9):895. https:\/\/doi.org\/10.3390\/medicina57090895","journal-title":"Med (Kaunas)"},{"issue":"7","key":"1499_CR12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","volume":"136","author":"DY Hsu","year":"2016","unstructured":"Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016) Morbidity and mortality of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis in United States adults. J Invest Dermatol 136(7):1387\u20131397. https:\/\/doi.org\/10.1016\/j.jid.2016.03.023","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1499_CR13","doi-asserted-by":"publisher","first-page":"103282","DOI":"10.1016\/j.annder.2024.103282","volume":"151","author":"S Ingen-Housz-Oro","year":"2024","unstructured":"Ingen-Housz-Oro S, Matei I, Gaillet A, Gueudry J, Zaghbib K, Assier H et al (2024) French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis). Ann Dermatol Venereol 151(2):103282. https:\/\/doi.org\/10.1016\/j.annder.2024.103282","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"1499_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes DJAR, Troc\u00f3niz IF, Ciccolini J, van Hasselt JGC (2019) Clinical pharmacokinetics and pharmacodynamics of Immune Checkpoint inhibitors. Clin Pharmacokinet 58(7):835\u2013857. https:\/\/doi.org\/10.1007\/s40262-019-00748-2","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1499_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200001060-00003","volume":"1","author":"PO Fritsch","year":"2000","unstructured":"Fritsch PO, Sidoroff A (2000) Drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis. Am J Clin Dermatol 1(6):349\u2013360. https:\/\/doi.org\/10.2165\/00128071-200001060-00003","journal-title":"Am J Clin Dermatol"},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S1081-1206(10)60789-2","volume":"97","author":"B Khalili","year":"2006","unstructured":"Khalili B, Bahna SL (2006) Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 97:272\u2013280 quiz 281\u2013\u2009273, 320","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"597761","DOI":"10.3389\/fimmu.2021.597761","volume":"12","author":"YO Hsu","year":"2021","unstructured":"Hsu YO, Lu KL, Fu Y, Wang C-W, Lu C-W, Lin Y-F, Chang W-C, Yeh K-Y, Hung S-I, Chung W-H, Chen C-B (2021) The roles of immunoregulatory networks in severe drug hypersensitivity. Front Immunol 12:597761","journal-title":"Front Immunol"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.06.005","volume":"53","author":"N Okiyama","year":"2014","unstructured":"Okiyama N, Katz SI (2014) Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun 53:1\u20139. https:\/\/doi.org\/10.1016\/j.jaut.2014.06.005","journal-title":"J Autoimmun"},{"issue":"4","key":"1499_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","volume":"44","author":"KL Vivar","year":"2017","unstructured":"Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L (2017) Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 44(4):381\u2013384. https:\/\/doi.org\/10.1111\/cup.12876","journal-title":"J Cutan Pathol"},{"issue":"2","key":"1499_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5415\/apallergy.0000000000000131","volume":"14","author":"YTH Pham","year":"2024","unstructured":"Pham YTH, Vu MT, Nguyen AQ, Trinh PN, Tran MH, Chu HC et al (2024) Pembrolizumab-induced Stevens-Johnson syndrome\/Toxic epidermal necrolysis in a Vietnamese patient with nonsmall-cell lung cancer. Asia Pac Allergy 14(2):84\u201389. https:\/\/doi.org\/10.5415\/apallergy.0000000000000131","journal-title":"Asia Pac Allergy"},{"issue":"2","key":"1499_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","volume":"18","author":"C Lonjou","year":"2008","unstructured":"Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99\u2013107. https:\/\/doi.org\/10.1097\/FPC.0b013e3282f3ef9c","journal-title":"Pharmacogenet Genomics"},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/wound.2019.0977","volume":"9","author":"OA Charlton","year":"2020","unstructured":"Charlton OA, Harris V, Phan K, Mewton E, Jackson C, Cooper A (2020) Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle) 9:426\u2013439","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"3\u2013S","key":"1499_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.23750\/abm.v90i3-S.8165","volume":"90","author":"L Liotti","year":"2019","unstructured":"Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F et al (2019) Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed 90(3\u2013S):52\u201360. https:\/\/doi.org\/10.23750\/abm.v90i3-S.8165","journal-title":"Acta Biomed"},{"issue":"17","key":"1499_CR24","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"2","key":"1499_CR25","doi-asserted-by":"publisher","first-page":"100478","DOI":"10.1016\/j.currproblcancer.2019.05.001","volume":"44","author":"R Kumar","year":"2020","unstructured":"Kumar R, Bhandari S (2020) Pembrolizumab induced toxic epidermal necrolysis. Curr Probl Cancer 44(2):100478. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.05.001","journal-title":"Curr Probl Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01499-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:04:08Z","timestamp":1735909448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01499-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":25,"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01499-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}